Case of De Novo Nail Psoriasis Triggered by the Second Dose of Pfizer-BioNTech BNT162b2 COVID-19 Messenger RNA Vaccine

    September 2021 in “ JAAD Case Reports
    Jose W. Ricardo, Shari R. Lipner
    Studysummary This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results